» Articles » PMID: 34943834

DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy

Overview
Journal Cells
Publisher MDPI
Date 2021 Dec 24
PMID 34943834
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

In the last decade, the sequence-specific transcription factor double homeobox 4 (DUX4) has gone from being an obscure entity to being a key factor in important physiological and pathological processes. We now know that expression of DUX4 is highly regulated and restricted to the early steps of embryonic development, where DUX4 is involved in transcriptional activation of the zygotic genome. While DUX4 is epigenetically silenced in most somatic tissues of healthy humans, its aberrant reactivation is associated with several diseases, including cancer, viral infection and facioscapulohumeral muscular dystrophy (FSHD). DUX4 is also translocated, giving rise to chimeric oncogenic proteins at the basis of sarcoma and leukemia forms. Hence, understanding how DUX4 is regulated and performs its activity could provide relevant information, not only to further our knowledge of human embryonic development regulation, but also to develop therapeutic approaches for the diseases associated with DUX4. Here, we summarize current knowledge on the cellular and molecular processes regulated by DUX4 with a special emphasis on FSHD muscular dystrophy.

Citing Articles

Genetic variation in patent foramen ovale: a case-control genome-wide association study.

Dong B, Li Y, Ai F, Geng J, Tang T, Peng W Front Genet. 2025; 15:1523304.

PMID: 39872005 PMC: 11769951. DOI: 10.3389/fgene.2024.1523304.


SIX transcription factors are necessary for the activation of DUX4 expression in facioscapulohumeral muscular dystrophy.

Fox A, Oliva J, Vangipurapu R, Sverdrup F Skelet Muscle. 2024; 14(1):30.

PMID: 39627769 PMC: 11613756. DOI: 10.1186/s13395-024-00361-3.


Integrating D4Z4 methylation analysis into clinical practice: improvement of FSHD molecular diagnosis through distinct thresholds for 4qA/4qA and 4qA/4qB patients.

Strafella C, Megalizzi D, Trastulli G, Proietti Piorgo E, Colantoni L, Tasca G Clin Epigenetics. 2024; 16(1):148.

PMID: 39438900 PMC: 11520157. DOI: 10.1186/s13148-024-01747-2.


The role(s) of NF-Y in development and differentiation.

Dolfini D, Imbriano C, Mantovani R Cell Death Differ. 2024; 32(2):195-206.

PMID: 39327506 PMC: 11802806. DOI: 10.1038/s41418-024-01388-1.


D4Z4 Hypomethylation in Human Germ Cells.

Potabattula R, Durackova J, Kiessling S, Michler A, Hahn T, Schorsch M Cells. 2024; 13(17.

PMID: 39273067 PMC: 11394335. DOI: 10.3390/cells13171497.


References
1.
Wagner K . Facioscapulohumeral Muscular Dystrophies. Continuum (Minneap Minn). 2019; 25(6):1662-1681. DOI: 10.1212/CON.0000000000000801. View

2.
Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O . Highly accurate protein structure prediction with AlphaFold. Nature. 2021; 596(7873):583-589. PMC: 8371605. DOI: 10.1038/s41586-021-03819-2. View

3.
Clemen C, Herrmann H, Strelkov S, Schroder R . Desminopathies: pathology and mechanisms. Acta Neuropathol. 2012; 125(1):47-75. PMC: 3535371. DOI: 10.1007/s00401-012-1057-6. View

4.
Lim K, Yokota T . Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy. Front Pharmacol. 2021; 12:642858. PMC: 7996372. DOI: 10.3389/fphar.2021.642858. View

5.
Bosnakovski D, Gearhart M, Toso E, Ener E, Choi S, Kyba M . Low level DUX4 expression disrupts myogenesis through deregulation of myogenic gene expression. Sci Rep. 2018; 8(1):16957. PMC: 6240038. DOI: 10.1038/s41598-018-35150-8. View